A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis

Herman, Jorge Acevedo; Khalighinejad, Farnaz; York, Katherine; Radu, Irina; Morales, Idanis Berrios; Ionete, Carolina; Hemond, Christopher C.

doi:10.1016/j.msard.2020.102619

Cited by 16 publications

(13 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After an average follow up of 22 months, it was observed a statistically significant change in physical disability of 0.5 points after alemtuzumab infusion on EDSS scale, similar to that reported by other reallife studies (Frau et al, 2019;Hyun et al, 2019;Zmira et al, 2020), and 65% of patients experienced confirm disability improvement. The percentage of patients that presented a sustained disability improvement is slightly higher than has been reported by a Post-Hoc CARE-MS study (Hunter et al, 2021) which reported that over 9 years 43% experienced confirmed disability improvement and is higher than reported by other real-life studies which reported an improvement between 14% and 27.5% (Herman et al, 2021;Hyun et al, 2019;Prosperini et al, 2018;Theodorsdottir et al, 2021). Future research should study whether the high percentage of patients improving in this research could be related to unique cultural and genetic of Colombian people.…”

Section: Discussioncontrasting

confidence: 56%

Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia

Bonitto

Ayala

Botero

2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 56%

Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia

Bonitto

Ayala

Botero

2022

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…However, comparison between studies is not straightforward due to different study protocols and varying follow-up times. In this report, four additional studies in which at least some patients had received previous or off-label doses of alemtuzumab, as well as two studies not reporting the dose of alemtuzumab, were not included for comparison [35][36][37][38][39][40].…”

Section: Discussionmentioning

confidence: 99%

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

Rauma

Mustonen

Seppä³

et al. 2021

J Neurol

View full text Add to dashboard Cite

Background Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. Methods In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Results Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 months and exceeded 24 months in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1–3, respectively. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. Conclusions SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.

show abstract

“…Two large Phase III trials and subsequent 9-year extensions have shown the sustained superiority of this drug on neurological disability, relapse rate and MRI outcomes, compared with interferon-beta 1 [2]. Recent real-world data confirmed the results of the registration studies [3]. However, the benefits of this therapy are counterbalanced by a significant incidence of adverse events, the most common of which regard secondary autoimmunity and affect up to 40% of patients.…”

Section: Introductionmentioning

confidence: 92%

Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients

Borriello

Ianniello

Toosy

2021

IJERPH

View full text Add to dashboard Cite

Alopecia Universalis (AU) is the most severe form of Alopecia Areata and is caused by cytotoxic T-cells reacting with follicular autoantigens, producing complete loss of scalp and body hair. Alemtuzumab is a highly efficacious monoclonal antibody used in the treatment of Multiple Sclerosis (MS), but it causes secondary autoimmunity in up to 40% of patients. Many factors are believed to contribute to this process, but pathogenic mechanisms are not well clear. To date, three cases of AU after treatment with Alemtuzumab have been reported. In this paper we report the cases of two patients who developed AU 12 months after the second cycle of Alemtuzumab, with a review of the literature. One year after the end of the second cycle, two female patients in their thirties experienced complete hair loss. The first case was temporally associated with a significant drop in vitamin D (VD) levels. The second case was accompanied by joint swelling. Both patients had thyroid alterations and showed no hair regrowth after a 2-year follow-up. AU must be considered among the secondary autoimmune manifestations of Alemtuzumab treatment. We emphasize the need for appropriate patient screening and thorough clinical surveillance for factors predisposing patients to secondary autoimmunity.

show abstract

A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis

Cited by 16 publications

References 28 publications

Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia

Real-life evidence of treatment with alemtuzumab in patients diagnosed with relapsing-remitting multiple sclerosis in Colombia

Safety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients

Alopecia Universalis Occurring after Alemtuzumab Treatment for Multiple Sclerosis. A Two-Year Follow-Up of Two Patients

Contact Info

Product

Resources

About